Purpose: Thermal tissue ablation with radio frequency energy is an experimental treatment of renal tumor. We report early results of an ongoing trial of percutaneous radio frequency ablation for small renal tumors.
tumor is variable but those less than 3 cm. rarely metasta-The safety and preliminary efficacy of radio frequency abla size. [1] [2] [3] [4] [5] Management options for small renal masses include tion have led to an ongoing trial of percutaneous radio fre observation, experimental ablation and surgical removal.
quency ablation in select patients with small renal tumors.
Experimental treatment of small renal tumors includes in
The need for intervention less morbid than recurrent surgery, situ ablation with high intensity focused ultrasound, cryo-dialysis and/or transplantation is particularly acute for patients therapy or radio frequency energy. 6 -8 Although high inten-with hereditary predisposition to renal cell carcinoma, for ex sity focused ultrasound for renal tumor has yet to be devel-ample von Hippel-Lindau disease or hereditary papillary renal oped clinically, promising early reports of cryotherapy for cancer. Multiple recurrent renal tumors may develop in these renal tumors have been published. 7, 9 A vast clinical experi-patients during a lifetime and, thus, form an ideal group in ence has been obtained with radio frequency ablation of liver which to study minimally invasive options, such as radio fre neoplasms but renal tumor radio frequency ablation is still in quency ablation. We continue to provide surgical extirpation as infancy. 10, 11 Since Zlotta et al introduced radio frequency a standard of care for hereditary renal tumors greater than 3 ablation for human renal tumor in 1997, 12 early results of cm. in diameter. 5 Percutaneous radio frequency ablation is ofpercutaneous radio frequency ablation as monotherapy for fered for smaller solid tumors that demonstrate growth during a 1-year period, and initial results are presented.
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MATERIALS AND METHODS
issue for which category 1 CME credits can be earned. In structions for obtaining credits are given with the questions
Patients with a solid renal tumor 3 cm. or less in diameter on pages 312 and 313.
on computerized tomography (CT) were eligible for the study 10 if the tumor demonstrated growth during at least 1 year and had no significant cystic component. All tumors, including those centrally located next to the collecting system, were evaluated for treatment. An interventional radiologist (B. J. W.) determined whether the tumor was percutaneously accessible and safely treatable. Lesions contiguous to bowel or the great vessels were considered unsuitable for treat ment. In addition, to be in our study each patient had to have 24-hour creatinine clearance greater than 60 ml. per minute or serum creatinine less than 2.0 mg./dl., undergo standard laboratory evaluation and have a recent CT that was 3 months or less from the date of the procedure. There were 3 patients who had a solitary kidney. Our study met internal review board approval and started accruing cases in the autumn of 1999. Informed consent was obtained from each patient.
Patients received intravenous hydration the night before treatment, as well as antibiotic prophylaxis with oral cipro floxacin or intravenous ampicillin and gentamicin. Our qua ternary referral center recruits patients from all over North America for clinical studies. Therefore, patients were not allowed to travel long distances home until the day after the procedure. A 3 to 5 day outpatient course of oral ciprofloxacin was given if the thermal lesion contacted the collecting sys tem, and outpatient oral pain medications were prescribed as necessary. A followup visit was scheduled at 2 months after the procedure, at which time serum biochemistry, urinalysis, and before and after contrast abdominal CT were obtained. Maximal lesion diameters in the horizontal plane were aver aged and used to calculate lesion volume. Contrast CT after the procedure was obtained 80 to 100 seconds after a 120 cc injection of nonionic IV contrast (Oxilan, Cook, Inc., Bloom ington, Indiana). Change in enhancement was defined as the difference between post-contrast and post-contrast HU in the lesion.
A single radiologist with extensive percutaneous radio fre quency ablation experience (B. J. W.) performed all treat ments at the Interventional Radiology suite. Conscious seda tion was administered to patients in standard fashion with midazolam, fentanyl and droperidol for all but 2 procedures, which required deep sedation or general anesthesia. Routine hemodynamic monitoring was performed in addition to neu rological examination for treatment areas near the psoas muscle. Treatment was performed with ultrasound guidance alone in 9 patients or a combination of CT with or without contrast as needed and real-time ultrasound in 15. The RITA Model 500 electrosurgical generator and RITA Model 70 co axial probe were used for all treatments except the first 2, in which the Model 30 probe system was used (RITA Medical Systems, Inc., Mountain View, California). The Model 500 generator delivers 50 W., 460 kHz. radio frequency energy, and the Model 30 and 70 probes are insulated 15 gauge coaxial needles consisting of an array of deployable elec trodes ( fig. 1 ). Therapy is monitored with feedback from temperature sensitive thermocouples at the treatment mar gin. Microbubble formation in the treatment area on realtime ultrasound provided a rough estimate of treatment vol ume, as did immediate CT after treatment, which was performed in 16 patients.
A 22 gauge tandem needle was used as a guide for difficult to-image lesions, followed by a 15 gauge RITA probe. The multielectrodes were then extruded to 2 to 3 cm. diameters, and radio frequency energy was delivered with a dispersive electrode grounding pad placed on the thigh or buttock. Tar get probe temperature was set at 100C. Tumors were heated to a maximum wattage of 50 to reach tissue temperatures greater than 70C for a 10 to 12-minute cycle. A second 10 to 12-minute radio frequency cycle was applied to each tumor, with the electrodes repositioned if necessary. For tumors close to 3 cm. in diameter and deep medullary tumors a third 10 to 12-minute cycle was applied if tissue temperatures failed to be maintained or achieved. Tumors not reaching at least 70C at the end of therapy were considered poorly treated. Adjacent blood vessels can "insulate" the tumor, preventing proper heating. Replacement of the needle in the tumor or rotation of the needle tines can sometimes improve tumor heating. Finally, as the treatment probe is withdrawn, radio frequency energy is again applied to cauterize the intrapa renchymal needle track to limit back bleeding and external needle track to limit tumor seeding.
Patients undergo imaging at 3, 6 and 12 months after treatment to follow the evolution of the managed tumor. Serum creatinine, creatinine clearance and differential renal scan are obtained at 6 and 12-month followup. Patients with enhancing enlarging tumors after therapy may undergo retreatment with radio frequency ablation or surgical resec tion. All data are presented as mean values plus or minus standard deviation (SD). The Wilcoxon matched pairs signed rank test was used to analyze differences in various param eters before and after treatment with commercial software.
RESULTS
Treatment.
A total of 26 patients met the criteria for entry into the trial. There were 5 patients who had tumors in positions that were determined to be unsafe for percutaneous radio frequency ablation. Of the treated patients there were 13 men and 8 women with a mean age of 39 years. Due to referral patterns at our institution, all patients in this series had hereditary forms of renal cell carcinoma, including von Hippel-Lindau disease in 19 and hereditary papillary renal cancer in 2. A total of 24 renal tumors were managed percu taneously (table 1) . Each tumor was treated only once, with 1 ablated in 18 patients and 2 in 3. Of the patients with greater than 1 tumor treated 2 underwent simultaneous treatment of tumors in the same kidney and 1 had a tumor in each kidney treated 6 months apart. Radio frequency ablation was never Of the 24 ablations 19 were considered satisfactory by a quality of treatment assessment at the treatment site by the interventional radiologist. A satisfactory treatment was one in which the lesion was accurately targeted and tissue tem peratures 70C or greater were maintained at all probe elec trodes during therapy. In 5 cases optimal tissue temperature was either not reached or maintained at each electrode and considered poor treatment. During the procedure, managed areas became progressively hyperechogenic on ultrasound, which provided a rough visual method of monitoring treat ment progress and probe location ( fig. 3) .
Treatment efficacy. Preliminary efficacy was assessed with abdominal CT 2 months after treatment (figs. 4 and 5). There were 2 radiographic parameters evaluated during this inter val, including a change in lesion enhancement (difference in HU) and lesion size (table 2) 3 (range 1.6 to 14.1 and 0.9 to 10.9, respectively, p res = 0.002) after treatment (median 4.2). Of the 5 tumors with focal areas of th fo persistent enhancement on 2-month CT 4 were thought to have been unsatisfactorily ablated by the treating radiolo gist. A fifth tumor considered satisfactorily managed was focally enhanced 2 months after treatment (table 2). Con versely, 1 tumor that did not enhance after radio frequency ablation was thought to have been inadequately ablated after the procedure, which was due to tumor heating to only 60 to 65C. Other than these 2 examples, immediate assessment of management at the treatment site was predictive of 2-month ablation success with imaging criteria. Clinically and radio graphically, neither metastatic disease nor any signs of tu mor in the treatment tracks were noted on followup.
Effects on the kidney. Urine dipstick and microscopic anal yses were performed before and 2 months after radio fre quency ablation in 17 patients. No patients had microscopic hematuria greater than 5 red blood cells per high power field but 4 had microscopic proteinuria (1+) on dipstick analysis that was not present before radio frequency ablation. There was 1 patient who had an episode of gross hematuria 2 hours after the procedure. The patient had a normal urinalysis 2 months later without interval complaints. The mean serum creatinine of the group did not change 2 months after radio frequency ablation (1.0 cy ab ± 0.2 mg./dl. [range 0.6 to 1.4 and 0.7 to 1.3], p = 0.9, normal range 0.9 to 1.4), and no patient had an increase in serum creatinine greater than 0.1 mg./dl. ase Complications. All patients were medically ready for dis charge from the hospital within 24 hours of radio frequency ablation. Each patient was discharged home the day after treatment, except for 1 who stayed a day longer for social reasons. The typical patient had nausea and mild pain for 4 to 8 hours after the procedure but pain at the treatment site was widely variable and not predictable by size or location. Prior ipsilateral flank surgery was associated with a higher degree of pain after the procedure. Nausea was the most common complaint during this time, and experienced by a majority of the patients and possibly related to sedatives that were used for the procedure. Nevertheless, most patients were able to tolerate dinner the night of the procedure and all tolerated a regular diet by morning. Flank pain postopera tively was described as a mild to moderate burning, which also resolved by morning.
Minor complications postoperatively occurred in 4 pa tients, including pain on flexion of the hip on the treated side in 2 and areas of ipsilateral cutaneous flank numbness 2. Pain on thigh flexion resolved by 48 hours and 2 weeks, respectively, whereas the areas of cutaneous numbness per sisted at 2-month followup. Treatment proximity to psoas and ilioinguinal or iliohypogastric nerves may have predis posed to these minor complications in patients with tumors abutting these areas. Another patient passed a dark stool 1-week postoperatively from an upper gastrointestinal source.
There were no clinical or radiographically detected major complications. Specifically, no damage to adjacent organs or major structures was noted on imaging during, immediately after or 2 months after the procedure except in a few cases. A small (1.5 cm.) perinephric hematoma was noted immedi ately after 1 case, which resolved uneventfully by 2-month CT. We attempted to manage several mm. margin surround ing each tumor. However, in 4 cases followup CT demon strated slightly more extensive collateral damage to the ip silateral kidney parenchyma. These areas were small compared to remaining ipsilateral normal kidney paren chyma, which was less than 10%, and were usually wedge shaped, consistent with radio frequency ablation induced ischemic damage to the local intra-arterial system. There were 2 patients who had thin rims, which were less than 0.5 cm., of neighboring liver ablated. One exophytic suprarenal tumor was managed without radiographic damage to the neighboring adrenal gland. No damage to the main renal arterial or venous system was noted.
DISCUSSION
Preliminary experience with percutaneous radio frequency ablation for small renal tumors is presented. There were 24 tumors managed in 21 patients with hereditary renal cell carcinoma. Percutaneous radio frequency ablation was of fered to obviate or delay surgery, or as an alternative to observation. The feasibility, preliminary efficacy and mini mal morbidity of percutaneous radio frequency ablation are demonstrated. Treatment was well tolerated, and patients had a short recovery time that was less than 24 hours. At 2-month followup 19 of 24 treated lesions showed no signifi cant contrast enhancement and had become smaller in size. No clinically significant renal or collateral damage was de tected by serum, urine or CT analysis. No urinary fistulas were observed.
Tumor destroyed with radio frequency ablation or cryo therapy may take months to regress, while the surgical bed after open partial nephrectomy may leave a defect that en hances on CT. 7, 15 It is encouraging that all but 1 (18 of 19) of the tumors thought to have been satisfactorily managed at the time of the procedure, with tissue temperatures 70C or greater, lost contrast enhancement 2 months after treat ment, with a difference in HU of less than 12. The clinical significance of focal contrast uptake in the remaining tumors is not known. However, hepatic radio frequency ablation HU 69) . B, during radio frequency ablation. C, 2 months after radio frequency ablation. After treatment lesion has decreased in diameter to 1.6 cm. (white arrow) and lost contrast enhancement (difference in HU 4). Cauterized needle track is still visible 2 months after ablating central tumor (white arrow). studies suggest that the lack of contrast enhancement on CT pathologically correlates with complete tumor necrosis. Long-term clinical and radiographic followup will be required to determine the natural history of renal tumors managed with radio frequency ablation.
Radio frequency ablation induces ionic agitation, frictional heat and cell death by coagulative necrosis. 6, 12, 16, 17 Patho logical analysis done in 24 hours of renal tumor radio fre quency ablation demonstrates pyknosis, stromal edema, and loss of nucleoli and nuclear detail in the treatment zone. 6, 18 Later, changes consistent with coagulative necrosis become more apparent. 12, 17, 18 In the clinical treatment of liver tu mors the lack of enhancement on CT correlated with patho logical coagulative necrosis to within 2 mm., while ultra sound was not an accurate predictor of the treatment zone. 18 Interstitial saline has been used for electrode augmentation in the kidney. 19 However, in our experience this method is not necessary for small tumors, and may result in less pre dictable and uniform thermal lesions. Future analysis of treatment parameters, including probe type, tissue temper ature and impedance, tumor location, and imaging, will bet ter define the requirements for successful radio frequency ablation of human renal tumor.
A recent series of 9 tumors in 8 patients demonstrated the short-term efficacy of large renal tumor radio frequency ab lation with a water cooled radio frequency system.
14 That system has 200 W. and a single 17.5 gauge needle probe internally perfused with chilled saline to limit charring and increase energy deposition. In this study ablation was more complete for exophytic tumors and the 3 tumors 3 cm. or less in diameter, while larger tumors required staged manage ment. There is no doubt that the smaller and more uniform tumors in our series facilitated 1 session radio frequency ablation. Exophytic tumors were more successfully treated in our series as well but 10 of 14 central, including medullary or cortico-medullary, tumors were also satisfactorily ablated with 1 session. Management of anterior tumor was limited by concern regarding heat effects on contiguous bowel, ureter or hilar vessels. Nevertheless, 5 anterior tumors were treated in our series, including 3 that show no enhancement at 2-month followup. For anterior and/or exophytic tumors a generous amount of perinephric fat may insulate the treated area and shield adjacent structures from collateral damage. For pa tients in whom percutaneous access is difficult or hazardous, for example thin patients with anterior tumors, laparoscopy assisted radio frequency ablation may become a reasonable option.
Currently, several companies market more powerful en ergy delivery systems and various probes capable of up to 5 cm. thermal ablation. Our study has now broadened to in clude these higher wattage radio frequency ablation systems as well as probes of various configurations. In the future treatment failures, and complications might be reduced with radio frequency delivery systems more precisely tailored to specific tumors and locations. Higher wattage systems may allow ablative target temperatures to be reached in virtually all tumors, regardless of location or vascularity.
Current standards dictate that patients with hereditary renal neoplasms be observed until the largest tumor reaches 3 cm., at which time all lesions in that kidney are enucleated. With this strategy we have seen no metastatic renal cancer in greater than 52 patients with hereditary renal cancer to date. 5, 20 Percutaneous radio frequency ablation may provide a new alternative for renal masses approaching this 3 cm. threshold and also be an option for sporadic renal tumor in poor surgical candidates.
Our group has performed greater than 1,000 tumor enucle ations in patients with von Hippel-Lindau disease and heredi tary papillary renal cancer, and found tumor histology in these cohorts to be entirely reproducible. Solid renal tumors on CT in patients with von Hippel-Lindau disease are invariably clear cell neoplasms, and in families with hereditary papillary renal cancer represent basophilic papillary renal cell carcinoma.
21, 22
Thus, tumor histology in our present series was predictable without resorting to biopsy before treatment. Biopsy after treat ment was not performed due to sampling error and morbidity concerns. Instead, the study algorithm included the interval before and after contrast imaging, followed by repeat radio frequency ablation for any lesion that persistently enhanced or surgery for any that grew greater than 3 cm. Although this series is small and preliminary, we remain cautiously optimis tic about these early results. Higher patient accrual and further followup will determine whether radio frequency ablation pro vides efficacious treatment of small renal tumors in specific clinical settings.
CONCLUSIONS
Radio frequency ablation of small renal tumors is mini mally morbid and well tolerated in patients with percutane ously accessible lesions. The vast majority of managed tu mors did not enhance and had decreased or stabilized in size on 2-month followup CT. The natural history of managed lesions and predictors of successful radio frequency ablation treatment outcome remain to be determined. If long-term results are favorable radio frequency ablation should prove to be an attractive treatment option for small renal masses in patients at risk for multiple renal tumors or with other relative contraindications to surgery.
Kathy Hurley and Igor Mikityansky provided technical assis tance. Drew Pautler designed the illustrations for figure 2. EDITORIAL COMMENT New minimally invasive technologies are being applied to nephron sparing surgery for renal tumors to decrease operating time, pain, morbidity and hospital stay. Tumor ablative treatment modalities include cryosurgery, radio frequency ablation, high intensity focused ultrasound, and laser and microwave coagulation. These modalities are being administered laparoscopically or percutaneously and, ul timately, complete extracorporeal methods may be developed. Each of these modalities is limited by the ability to image the destructive process precisely as it is being administered, thereby minimizing injury to normal adjacent parenchyma, while ensuring complete destruction of the offending lesion.
The ablative modality with which the most experience has been gained for treatment of renal tumors is cryosurgery. Initial experi mental studies at our center evaluated the efficacy of intraparenchy mal cryoablative therapy with or without renal artery occlusion in mongrel dogs. 1 Effective renal tissue ablation was confirmed at the treatment site in all instances. Renal artery occlusion did not signif icantly alter the freezing process and provided no practical advan tage. Our group subsequently embarked on a clinical trial of laparo scopic renal cryoablation in carefully select patients with a single small (less than 4 cm.), solid, peripheral localized renal tumor. This trial was initiated in 1997, and follow-up after treatment is greater than 3 years in many patients (reference 7 in article). Our patients have been followed closely with sequential magnetic resonance im aging and percutaneous biopsy of the cryoablated renal tumor at 6 months postoperatively. In our initial series of 50 patients sequential magnetic resonance imaging demonstrated gradual contraction in the size of the cryolesion in all but 1 patient, and percutaneous biopsy of the cryoablated renal tumor site demonstrated residual malignancy in this patient. All other postoperative percutaneous biopsies have been negative for malignancy. There have been no other instances of tumor recurrence, and all patients are being subjected to close clinical and radiographic followup.
Pavlovich et al describe preliminary outcome data with percuta neous Radio Frequency Ablation for small renal tumors. The study population comprised patients with von Hippel-Lindau disease with solid tumors less than 3 cm. This study group is appropriate since the risk of metastasis in this setting is low. The clinical trial was not preceded by evaluation of this technique in an experimental animal model. A total of 21 patients were treated with Radio Frequency Ablation, however, followup is only 2 months. The finding of persis tent CT enhancement on 5 renal tumors after Radio Frequency Ablation is of concern in regard to residual malignancy. We have not observed this finding in renal tumors ablated with cryotherapy. Percutaneous biopsy of the treatment site in these patients might enable earlier diagnosis and treatment of residual malignancy. Al though percutaneous Radio Frequency Ablation appears to be safe, it remains experimental until validation of tumor destruction is dem onstrated by longer term outcome data. Ultimately, any new nephron sparing treatment modality must demonstrate clinical and pathological success rates comparable to those reported after open partial nephrectomy before it can be considered as established ther apy for renal tumors.
